Overcoming hurdles in CRISPR gene editing to improve treatment
The new gene-editing tool CRISPR/Cas9 holds promise for new treatment of such genetic diseases as cystic fibrosis, muscular dystrophy and hemophilia. But to work well, it must be delivered across the cell membrane and into its nucleus, a process that can trigger cell defenses and'trap'CRISPR/Cas9, reducing its treatment potential. Now, a research team has designed a delivery system using nanoparticles to assist CRISPR/Cas9 across the membrane and avoid entrapment by cellular machinery. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - February 7, 2017 Category: Science Source Type: news

Overcoming hurdles in CRISPR gene editing to improve treatment
(University of Massachusetts at Amherst) The new gene-editing tool CRISPR/Cas9 holds promise for new treatment of such genetic diseases as cystic fibrosis, muscular dystrophy and hemophilia. But to work well, it must be delivered across the cell membrane and into its nucleus, a process that can trigger cell defenses and 'trap' CRISPR/Cas9, reducing its treatment potential. Now, Vincent Rotello's laboratory at UMass Amherst has designed a delivery system using nanoparticles to assist CRISPR/Cas9 across the membrane and avoid entrapment by cellular machinery. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - February 7, 2017 Category: Biology Source Type: news

Ban Sparks Panic Among Refugees Awaiting Urgent Medical Care in U.S. Ban Sparks Panic Among Refugees Awaiting Urgent Medical Care in U.S.
Al Ameen, a 33-year-old Iraqi refugee with hemophilia A has been living in Jordan awaiting medical care in the United States for two years. His condition is so advanced, his doctors have told him, that only a handful of facilities in the world can treat him.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 31, 2017 Category: Consumer Health News Tags: Family Medicine/Primary Care News Source Type: news

Cambridge gene therapy firm loses half of market cap on study results
Cambridge gene therapy firm Dimension Therapeutics on Tuesday announced disappointing results from a trial of its lead drug, cutting its market cap in half. Dimension (Nasdaq: DMTX) announced preliminary data from a small Phase 1/2 study of a drug for hemophilia B, showing that while the treatment was somewhat effective in boosting a blood-clotting protein, some patients experienced liver toxicity. The safety data appeared to raise serious concerns a mong investors. Shares of Dimension were down… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - January 31, 2017 Category: Pharmaceuticals Authors: Max Stendahl Source Type: news

Cambridge gene therapy firm loses half of market cap on study results
Cambridge gene therapy firm Dimension Therapeutics on Tuesday announced disappointing results from a trial of its lead drug, cutting its market cap in half. Dimension (Nasdaq: DMTX) announced preliminary data from a small Phase 1/2 study of a drug for hemophilia B, showing that while the treatment was somewhat effective in boosting a blood-clotting protein, some patients experienced liver toxicity. The safety data appeared to raise serious concerns a mong investors. Shares of Dimension were down… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - January 31, 2017 Category: Biotechnology Authors: Max Stendahl Source Type: news

Ban sparks panic among refugees awaiting urgent medical care in U.S.
SAN FRANCISCO/NEW YORK, (Reuters) - Al Ameen, a 33-year-old Iraqi refugee with hemophilia A, a genetic disorder that prevents proper blood clotting, has been living in Jordan awaiting medical care in the United States for two years. His condition is so advanced, his doctors have told him, that only a handful of facilities in the world can treat him. (Source: Reuters: Health)
Source: Reuters: Health - January 30, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Biogen ’s hemophilia spinoff launches this week. Here’s what you need to know.
With around 400 employees, $325 million in cash and two drugs on the market that generated nearly $850 million in sales in fiscal 2016, Biogen ’s hemophilia spinoff is not your average startup. The company, called Bioverativ, is set to compete its separation from the Cambridge drugmaker(Nasdaq: BIIB) and launch its own website on Wednesday. Shares of the company are already trading on the Nasdaq under the symbol “BIVVV.” In an inte rview, Bioverativ CEO John Cox, who previously served as Biogen’s… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - January 30, 2017 Category: Pharmaceuticals Authors: Max Stendahl Source Type: news

Biogen ’s hemophilia spinoff launches this week. Here’s what you need to know.
With around 400 employees, $325 million in cash and two drugs on the market that generated nearly $850 million in sales in fiscal 2016, Biogen ’s hemophilia spinoff is not your average startup. The company, called Bioverativ, is set to compete its separation from the Cambridge drugmaker(Nasdaq: BIIB) and launch its own website on Wednesday. Shares of the company are already trading on the Nasdaq under the symbol “BIVVV.” In an inte rview, Bioverativ CEO John Cox, who previously served as Biogen’s… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - January 30, 2017 Category: Biotechnology Authors: Max Stendahl Source Type: news

Haemophilia: One in five at risk from internal bleeding caused by rare blood disorder
HAEMOPHILIA is an inherited bleeding disorder caused by a deficiency in one of the blood clotting factors. (Source: Daily Express - Health)
Source: Daily Express - Health - January 26, 2017 Category: Consumer Health News Source Type: news

Raising a Child with Hemophilia: Fifth Edition Now Available
LA Kelley Communications' groundbreaking book Raising a Child with Hemophilia celebrates its 25th anniversary with a newly revised fifth edition. The first guidebook about hemophilia written by a...(PRWeb January 26, 2017)Read the full story at http://www.prweb.com/releases/2017/01/prweb14011379.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - January 26, 2017 Category: Pharmaceuticals Source Type: news

Cancer, hepatitis treatments set for boost as China overhauls drugs list
SHANGHAI (Reuters) - China is set to add more than 300 new and traditional drugs to its list of medicines the state will help patients pay for, the first change in more than seven years that will boost treatments for cancer, kidney disease, hepatitis and haemophilia. (Source: Reuters: Health)
Source: Reuters: Health - January 26, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Sobi begins patient enrolment in A-SURE study haemophilia A treatment
Swedish Orphan Biovitrum (Sobi) has begun enrolling patients for the A-SURE study, which is designed to evaluate the effectiveness of Elocta compared to conventional FVIII products in the prophylactic treatment of patients with haemophilia A. (Source: Drug Development Technology)
Source: Drug Development Technology - January 23, 2017 Category: Pharmaceuticals Source Type: news

Poisoned, shot and beaten: why cyanide alone may have failed to kill Rasputin
Theories around the death of Grigori Rasputin still abound 100 years after the event. We examine the scientific credibility of some of the claimsThe end of December marked the 100th anniversary ofthe death of Rasputin, the “mad monk of Russia”, or “lover of the Russian queen” if you believe theBoney M song, though you probably shouldn ’t. While the song is undoubtedly a floor-filler, unsurprisingly it is not exactly a reliable historical account of Rasputin’s life.Grigori Yefimovich Rasputin, a mystic and spiritual healer born in Pokrovskoe in Siberia, wielded huge influence over the Rus...
Source: Guardian Unlimited Science - January 13, 2017 Category: Science Authors: Kathryn Harkup Tags: Chemistry Forensic science Source Type: news

With gene therapy closing in on hemophilia, BioMarin expands in North Bay
Rare-disease drug developer BioMarin Pharmaceutical Inc. is expanding its Novato manufacturing facility as it pushes into a final clinical trial for its experimental gene therapy for hemophilia A. The facility, expected to come on line in the third quarter, is significant in the emerging field of gene therapy because only a few companies have taken on the commitment of actually making their drugs in-house. Most gene therapy companies have opted to use contract manufacturers, at least throug h clinical… (Source: bizjournals.com Health Care News Headlines)
Source: bizjournals.com Health Care News Headlines - January 9, 2017 Category: Health Management Authors: Ron Leuty Source Type: news

Spark reels in second $15M payment from Pfizer
Spark Therapeutics said Wednesday it has received a second $15 million payment from Pfizer, this one for hitting pre-specified safety and efficacy development milestones for an experimental gene therapy treatment of hemophilia B the company ’s are co-developing. The gene therapy candidate, called SPK-9001, has received breakthrough therapy and orphan product designations from the Food and Drug Administration. “We continue to make strong, tangible progress with our hemophilia pipeline, and achievement… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - January 4, 2017 Category: American Health Authors: John George Source Type: news

Katherine High talks gene therapy progress for hemophilia & inherited retinopathies
(Mary Ann Liebert, Inc./Genetic Engineering News) Gene therapy has shown some of its most promising early results in treating patients with hemophilia and inherited retinal disorders that cause vision loss and blindness, both important research and drug development targets during the career of Katherine High, M.D., President and Chief Scientific Officer of Spark Therapeutics. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - January 4, 2017 Category: Global & Universal Source Type: news

Gene therapy for liver disease advanced to human testing
Amy WallaceNEW ROCHELLE, N.Y., Dec. 30 (UPI) -- Liver-directed gene therapy using adeno-associated viral vectors to treat diseases like hemophilia have moved on to human testing. (Source: Health News - UPI.com)
Source: Health News - UPI.com - December 30, 2016 Category: Consumer Health News Source Type: news

Researchers Develop Potential Oral Treatment for Hemophilia
Title: Researchers Develop Potential Oral Treatment for HemophiliaCategory: Health NewsCreated: 12/29/2016 12:00:00 AMLast Editorial Review: 12/30/2016 12:00:00 AM (Source: MedicineNet Heart General)
Source: MedicineNet Heart General - December 30, 2016 Category: Cardiology Source Type: news

Gene therapy for liver disease advancing with the help of adeno-associated viral vectors
(Mary Ann Liebert, Inc./Genetic Engineering News) Liver-directed gene therapy delivered using adeno-associated viral (AAV) vectors to treat diseases such as hemophilia have advanced into human testing. The potential for continued technological improvements to expand the therapeutic applications of gene therapy to treat liver disorders and the remaining clinical challenges are examined in a comprehensive review article published in Human Gene Therapy. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 30, 2016 Category: Global & Universal Source Type: news

Potential oral treatment for hemophilia in early stage of development
HealthDay News University of Texas at Austin researchers created an oral treatment for one type of hemophilia, which is a serious, genetic bleeding disorder. (Source: Health News - UPI.com)
Source: Health News - UPI.com - December 30, 2016 Category: Consumer Health News Source Type: news

Researchers Develop Potential Oral Treatment for Hemophilia
Currently, genetic bleeding disorder is treated with injections Source: HealthDay Related MedlinePlus Page: Hemophilia (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - December 29, 2016 Category: Consumer Health News Source Type: news

Researchers Develop Potential Oral Treatment for Hemophilia
THURSDAY, Dec. 29, 2016 -- People with hemophilia have to endure painful injections every few days to stay alive, but a newly developed treatment may one day offer a simpler, cheaper and less painful alternative. University of Texas at Austin... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - December 29, 2016 Category: Journals (General) Source Type: news

Shire Announces FDA Approval of Adynovate(R) for use in Children and Surgical Settings
New FDA-approved indications for ADYNOVATE provides more hemophilia A patients access to proven prophylaxis with a simple, twice-weekly dosing schedule LEXINGTON, Massachusetts, December 27, 2016 -- (Healthcare Sales & Marketing Network) -- Shire plc (... Biopharmaceuticals, FDA Shire plc, ADYNOVATE, hemophilia A (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - December 27, 2016 Category: Pharmaceuticals Source Type: news

Coming soon to the Nasdaq: Biogen's hemophilia spinoff
The biggest life sciences company based in Massachusetts will soon spawn another publicly traded biotech with a similar ticker symbol. Cambridge-based Biogen (Nasdaq: BIIB) announced in May that it planned to spin off its hemophilia business, and the move was formally approved by the company’s board of directors on Dec. 20. The new firm, named Bioverativ, will start with around 400 employees and will be led by John Cox, who pre viously served as Biogen’s executive vice president of pharmaceutical… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - December 27, 2016 Category: American Health Authors: Max Stendahl Source Type: news

Coming soon to the Nasdaq: Biogen's hemophilia spinoff
The biggest life sciences company based in Massachusetts will soon spawn another publicly traded biotech with a similar ticker symbol. Cambridge-based Biogen (Nasdaq: BIIB) announced in May that it planned to spin off its hemophilia business, and the move was formally approved by the company’s board of directors on Dec. 20. The new firm, named Bioverativ, will start with around 400 employees and will be led by John Cox, who pre viously served as Biogen’s executive vice president of pharmaceutical… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - December 27, 2016 Category: Biotechnology Authors: Max Stendahl Source Type: news

Sporting activities and quality of life in children with hemophilia: an observational study - Cuesta-Barriuso R, Torres-Ortu ño A, Pérez-Alenda S, José Carrasco J, Querol F, Nieto-Munuera J.
The objective of this study was to assess the incidence of sports activities in the quality of life as perceived by children with hemophilia. ... (Source: SafetyLit)
Source: SafetyLit - December 26, 2016 Category: Global & Universal Tags: Age: Adolescents Source Type: news

Capsule for severe bleeding disorder moves closer to reality
Researchers are working to develop a pill to treat this serious inherited bleeding disorder. Oral delivery of the treatment--clotting factor IX--would allow individuals with type B hemophilia to swallow a pill rather than be subjected to several weekly injections of factor IX to control potentially fatal bleeding episodes. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - December 23, 2016 Category: Science Source Type: news

Roche boosted by haemophilia drug test
Swiss pharma group says treatment showed signs of outperforming others (Source: FT.com - Drugs and Healthcare)
Source: FT.com - Drugs and Healthcare - December 22, 2016 Category: Pharmaceuticals Source Type: news

Genentech’s Emicizumab for Hemophilia A Meets Primary Endpoint in Phase III Study
SOUTH SAN FRANCISCO, Calif.--(Healthcare Sales & Marketing Network)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the primary endpoint has been met for the Phase III HAVEN 1 study evaluating emicizumab prophylax... Biopharmaceuticals Genentech, Roche Group, emicizumab, HAVEN 1, hemophilia A (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - December 22, 2016 Category: Pharmaceuticals Source Type: news

Roche's emicizumab for haemophilia A meets primary endpoint in phase III study
Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the primary endpoint has been met for the phase III HAVEN 1 study evaluating emicizumab prophylaxis in people 12 years of age or older with haemophilia A and inhibitors to factor VIII. The study showed a statistically significant reduction in the number of bleeds over time in people treated with emicizumab prophylaxis compared to those receiving no prophylactic treatment. (Source: World Pharma News)
Source: World Pharma News - December 22, 2016 Category: Pharmaceuticals Tags: Featured Roche Business and Industry Source Type: news

Roche's emicizumab haemophilia drug succeeds in trial
ZURICH (Reuters) - Roche Holding AG's emicizumab drug for treating haemophilia A showed it worked in a phase III study, the Swiss drugmaker said on Thursday. (Source: Reuters: Health)
Source: Reuters: Health - December 22, 2016 Category: Consumer Health News Tags: healthNews Source Type: news

Roche ’s emicizumab for haemophilia A meets primary endpoint in phase III study
Roche today announced that the primary endpoint has been met for the phase III HAVEN 1 study evaluating emicizumab prophylaxis in people 12 years of age or older with haemophilia A and inhibitors to factor VIII. (Source: Roche Media News)
Source: Roche Media News - December 22, 2016 Category: Pharmaceuticals Source Type: news

Roche ’s emicizumab for haemophilia A meets primary endpoint in phase III study
Roche today announced that the primary endpoint has been met for the phase III HAVEN 1 study evaluating emicizumab prophylaxis in people 12 years of age or older with haemophilia A and inhibitors to factor VIII. (Source: Roche Investor Update)
Source: Roche Investor Update - December 22, 2016 Category: Pharmaceuticals Source Type: news

As nation ages, dementia is becoming a significant economic burden (SLIDESHOW)
Peter McDougal always thought of his father, Steven McDougal, as being one of the sharpest, most brilliant men around. Steven, a former chief of Atlanta-based U.S. Centers for Disease Control and Prevention’s Immunology branch in the division of HIV/AIDS, sexually transmitted diseases and tuberculosis laboratory research, identified the primary receptor for HIV in the 1980s, and he also helped slow the epidemic in people with hemophilia. He had not yet retired from the CDC when he was diagnosed… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - December 16, 2016 Category: American Health Authors: Ellie Hensley Source Type: news

Gene Therapy Offers Hope to Some Hemophilia Patients
Title: Gene Therapy Offers Hope to Some Hemophilia PatientsCategory: Health NewsCreated: 12/6/2016 12:00:00 AMLast Editorial Review: 12/7/2016 12:00:00 AM (Source: MedicineNet Heart General)
Source: MedicineNet Heart General - December 7, 2016 Category: Cardiology Source Type: news

Gene therapy offers hope to some hemophilia patients
HealthDay News Preliminary research suggests that a single dose of an experimental gene therapy may help patients with hemophilia B. (Source: Health News - UPI.com)
Source: Health News - UPI.com - December 6, 2016 Category: Consumer Health News Source Type: news

Gene Therapy Offers Hope to Some Hemophilia Patients
Small, preliminary trial suggests it may free hemophilia B patients from transfusions Source: HealthDay Related MedlinePlus Pages: Genes and Gene Therapy, Hemophilia (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - December 6, 2016 Category: Consumer Health News Source Type: news

Gene Therapy Offers Hope to Some Hemophilia Patients
TUESDAY, Dec. 6, 2016 -- Preliminary research suggests that a single dose of an experimental gene therapy may help patients with hemophilia B. As explained by the National Hemophilia Foundation, hemophilia B is a genetic disorder where people lack... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - December 6, 2016 Category: Journals (General) Source Type: news

NovoSeven ® resolved 96.5% of bleeds when initiated within one hour after bleed onset in people with haemophilia A or B with inhibitors
Novo Nordisk has announced that NovoSeven® (rFVIIa), a portable room temperature stable recombinant activated factor VIIa, resolved 96.5% of bleeds when initiated within one hour after onset of bleeding, demonstrating efficacy of early treatment in people with haemophilia A or B with inhibitors.(1) Efficacy also remained high for bleeds treated after 4 hours. (Source: World Pharma News)
Source: World Pharma News - December 6, 2016 Category: Pharmaceuticals Tags: Featured Novo Nordisk Business and Industry Source Type: news

CSL Behring reports positive Phase III PROLONG-9FP trial data of IDELVION to treat haemophilia B
Australian CSL's US biotherapeutics subsidiary CSL Behring has reported positive results from its Phase III PROLONG-9FP clinical development programme of IDELVION to treat haemophilia B. (Source: Drug Development Technology)
Source: Drug Development Technology - December 6, 2016 Category: Pharmaceuticals Source Type: news

Gene Therapy Shows Promise in Hemophilia B (CME/CE)
(MedPage Today) -- No infusions, major bleeds in preliminary trial (Source: MedPage Today Meeting Coverage)
Source: MedPage Today Meeting Coverage - December 5, 2016 Category: Journals (General) Source Type: news

After one dose of gene therapy, hemophilia B patients maintain near-normal levels of clotting factor
Researchers are reporting the highest and most sustained levels to date of an essential blood-clotting factor IX in patients with the inherited bleeding disorder hemophilia B. After receiving a single dose of an experimental gene therapy in a clinical trial, patients with hemophilia produced near-normal levels of clotting factor IX, allowing them to stop clotting factor infusions and to pursue normal activities of daily life without disabling bleeding episodes. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - December 3, 2016 Category: Science Source Type: news

After gene therapy, hemophilia B patients maintain near-normal levels of clotting factor
(Children's Hospital of Philadelphia) Researchers are reporting the highest and most sustained levels to date of an essential blood-clotting factor in patients with the inherited bleeding disorder hemophilia B. After receiving a single dose of an experimental gene therapy in a clinical trial, patients with hemophilia produced near-normal levels of clotting factor IX, allowing them to stop clotting factor infusions and to pursue normal activities of daily life without disabling bleeding episodes. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 3, 2016 Category: Global & Universal Source Type: news

CRISPR used for first time to correct clotting in newborn and adult mice
CRISPR/Cas9, a powerful genome editing tool, is showing promise for efficient correction of disease-causing mutations. For the first time, researchers have developed a dual gene therapy approach to deliver key components of a CRISPR/Cas9-mediated gene targeting system to mice to treat hemophilia B. This disorder is also called factor IX deficiency and is caused by a missing or defective clotting protein. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - November 30, 2016 Category: Science Source Type: news

Penn scientists use CRISPR for first time to correct clotting in newborn and adult mice
(University of Pennsylvania School of Medicine) CRISPR/Cas9, a powerful genome editing tool, is showing promise for efficient correction of disease-causing mutations. For the first time, researchers have developed a dual gene therapy approach to deliver key components of a CRISPR/Cas9-mediated gene targeting system to mice to treat hemophilia B. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - November 30, 2016 Category: Global & Universal Source Type: news

Researchers develop bioresorbable capsule for treating hemophilia
Researchers from the Cockrell School of Engineering at the University of Texas at Austin have developed a biodegradable capsule to deliver a protein therapy for hemophilia. The research, published in the International Journal of Pharmaceutics, could provide a cheaper, less painful alternative to injections or infusions. The capsule contains micro and nanoparticles which carry a protein therapy to treat hemophilia B. The disease is caused by a missing or defective factor IX, a clotting protein, in the blood. Access to the protein therapy is limited due to its cost and the complications brought on by needle-based drug d...
Source: Mass Device - November 28, 2016 Category: Medical Equipment Authors: Sarah Faulkner Tags: Drug-Device Combinations Pharmaceuticals Research & Development University of Texas at Austin Source Type: news

First-ever capsule to treat hemophilia developed
In the near future, hemophiliacs could be able to treat their disease by simply swallowing a capsule. Thanks to a new breakthrough, treatment for hemophilia can now be administered via a biodegradable system, a capsule, giving people affected by the hereditary bleeding disorder hope for a less expensive, less painful treatment option than conventional injections or infusions. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - November 28, 2016 Category: Science Source Type: news

CHMP Backs Lonoctocog Alfa (Afstyla) for Hemophilia A CHMP Backs Lonoctocog Alfa (Afstyla) for Hemophilia A
A European Medicines Agency committee has recommended marketing authorization for lonoctocog alfa for the prevention and treatment of bleeding in patients of all ages with hemophilia A.International Approvals (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - November 12, 2016 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news

Roche Hemophilia Drug Stumbles in Trials
Four patients experienced serious adverse events during a clinical trial of Roche's experimental hemophilia med, ACE910. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - November 3, 2016 Category: Pharmaceuticals Source Type: news

Adverse events in trial dent hopes for Roche hemophilia drug
LONDON (Reuters) - Four patients have suffered serious adverse events in a clinical trial of an experimental hemophilia medicine from Roche, the Swiss group said on Wednesday, clouding prospects for its potential blockbuster product. (Source: Reuters: Health)
Source: Reuters: Health - November 2, 2016 Category: Consumer Health News Tags: healthNews Source Type: news